# NCT02362997 (NCT02362997)

> Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: relapsed/refractory classical Hodgkin lymphoma, DLBCL or PTCL

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02362997
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Peripheral T-Cell Lymphoma
- Interventions: Pembrolizumab
- Enrollment: 82
- Primary outcome: Progression-free Survival After ASCT

## Indexed commentary on NCT02362997 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02362997